PubMed · Hepatology· Kris V Kowdley·· 3 天前
elafibranor使对熊去氧胆酸应答不完全的原发性胆汁性胆管炎患者碱性磷酸酶正常化：III期随机对照ELSPIRE试验结果
Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial.
AI 导读
III期随机对照试验ELSPIRE将92例对熊去氧胆酸应答不完全/不耐受、ALP>1至<1.67×ULN的原发性胆汁性胆管炎患者，双盲2:1随机至elafibranor 80 mg（n=62）或安慰剂（n=30）治疗52周。
来源：PubMed · Hepatology · pubmed.ncbi.nlm.nih.gov